FDA warned Amcyte Pharma over its website selling Nasitrol as an unapproved, misbranded COVID-19 drug.
What happened
FDA reviewed https://nasitrol.com/ on December 20, 2021. FDA found Nasitrol offered for sale in the United States with claims that it can mitigate, prevent, treat, diagnose, or cure COVID-19, including claims about an in vitro study and a clinical trial. FDA cited it as an unapproved new drug and a misbranded drug.
What FDA found
Nasitrol is an unapproved new drug because it is sold to treat COVID-19 without FDA approval.
section 505(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(a)Nasitrol is misbranded because its labeling misleadingly presents it as safe or effective for COVID-19.
section 502 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 352The product is introduced or delivered for introduction into interstate commerce despite being unapproved and misbranded.
sections 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 331(a) and (d)
What FDA wants
FDA tells Amcyte Pharma to take immediate action to stop selling any unapproved and unauthorized COVID-19 products and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the specific steps taken, an explanation of steps to prevent recurrence, and related documentation.
Who should pay attention
- online sellers of COVID-19-related health products
- companies making disease-treatment claims on product websites
- consumers and clinicians evaluating COVID-19 products
This is a summary. Read the original letter on fda.gov.